罗莫佐单抗与特立帕肽在骨质疏松合并CKD患者中的疗效与心血管安全性比较:目标试验模拟研究
本研究采用目标试验模拟设计,基于TriNetX美国研究网络数据,纳入40岁以上、eGFR<60 ml/min/1.73 m²的骨质疏松患者,经1:1倾向评分匹配后每组2045例。罗莫佐单抗较特立帕肽显著降低椎体骨折风险(HR 0.64,95%CI 0.42-0.98),且主要不良心血管事件(HR 0.82,95%CI 0.70-0.97)和心肌梗死(HR 0.77,95%CI 0.63-0.95)风险更低。非椎体骨折和髋部骨折风险无显著差异。
要点
- 罗莫佐单抗较特立帕肽降低CKD骨质疏松患者椎体骨折风险(HR 0.64)
- 罗莫佐单抗主要不良心血管事件和心肌梗死风险低于特立帕肽
- 非椎体骨折和髋部骨折风险两组无显著差异
核心结论
- 在骨质疏松合并CKD患者中,罗莫佐单抗比特立帕肽更有效降低椎体骨折风险,且主要心血管事件发生率更低。
研究设计与样本
- 采用目标试验模拟设计,基于TriNetX美国研究网络的回顾性队列研究。
- 纳入40岁及以上、骨质疏松且eGFR<60 ml/min/1.73 m²的患者,经1:1倾向评分匹配后每组2045例,采用Cox比例风险模型评估结局。
主要发现
- 罗莫佐单抗组椎体骨折风险显著低于特立帕肽组(HR 0.64;95%CI 0.42-0.98)。
- 非椎体骨折和髋部骨折风险两组无显著差异。
- 罗莫佐单抗组主要不良心血管事件风险降低(HR 0.82;95%CI 0.70-0.97)。
- 罗莫佐单抗组心肌梗死风险降低(HR 0.77;95%CI 0.63-0.95)。
- 结果在多数亚组和敏感性分析中基本一致。
临床怎么用
- 对于骨质疏松合并CKD(eGFR<60 ml/min/1.73 m²)患者,罗莫佐单抗可作为优先考虑以降低椎体骨折和心血管事件风险。
局限性
- 回顾性观察性设计存在残余混杂可能。
- 研究人群以eGFR<60 ml/min/1.73 m²定义CKD,未细分晚期CKD(如4-5期)的单独效应。
- 需要进一步前瞻性研究验证,尤其在晚期CKD患者中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Romosozumab was associated with lower vertebral fracture risk than teriparatide in patients with osteoporosis and CKD. No significant differences were observed in nonvertebral or hip fracture risk between treatment groups. Romosozumab was associated with lower risks of major adverse cardiovascular events and myocardial infarction compared with teriparatide. BACKGROUND: Osteoporosis commonly coexists with CKD, increasing skeletal fragility and cardiovascular risk. While romosozumab shows superior fracture prevention in general osteoporosis, evidence in CKD stages 3-5 patients remains limited. METHODS: Using a target trial emulation design, we conducted a retrospective cohort study leveraging the TriNetX US research network. Patients aged 40 years or older with osteoporosis and an eGFR<60 ml/min per 1.73 m 2 were included. After 1:1 propensity score matching, outcomes were assessed using Cox proportional hazards models. The primary effectiveness outcomes were nonvertebral and vertebral fractures within 12 months. The secondary outcome was hip fractures. Safety outcomes included major adverse cardiovascular events, myocardial infarction, stroke, and all-cause mortality. RESULTS: After propensity score matching, 2045 patients were included in each group. Romosozumab was associated with a significantly lower risk of vertebral fractures compared with teriparatide (hazard ratio [HR], 0.64; 95% confidence interval [CI], 0.42 to 0.98), whereas no significant differences were observed for nonvertebral or hip fractures. For cardiovascular safety, romosozumab was linked to a reduced risk of major adverse cardiovascular events (HR, 0.82; 95% CI, 0.70 to 0.97) and myocardial infarction (HR, 0.77; 95% CI, 0.63 to 0.95). These findings were generally consistent across most subgroups and sensitivity analyses. CONCLUSION: In patients with osteoporosis and CKD, romosozumab was more effective than teriparatide in reducing vertebral fracture risk and was associated with a lower incidence of major cardiovascular events. These findings support the potential dual benefits of romosozumab in this high-risk population and highlight the need for further prospective studies, particularly in those with advanced CKD.
引用
- Hung CH, Yang FY, Huang HE, et al. Comparative Effectiveness and Cardiovascular Safety of Romosozumab versus Teriparatide in Osteoporosis Patients with CKD: Target Trial Emulation Study. Clin J Am Soc Nephrol. 2026. PMID: 42584962. doi:10.2215/CJN.0000001168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。